Overview
Growth Differentiation Factor 15 (GDF15) and GDF11 are members of the TGF-β (Transforming Growth Factor beta) superfamily that have emerged as critical regulators of energy homeostasis, stress responses, and more recently, neuroprotection. Originally characterized for their roles in embryonic development, these cytokines have gained significant attention for their involvement in aging, metabolic disorders, and neurodegenerative diseases.
GDF15 and GDF11 Biology
Structural Features
GDF15 and GDF11 are secreted cytokines belonging to the TGF-β superfamily. They share structural homology with other family members but have distinct biological functions: 1GDF15 and aging: mechanisms and therapeutic potential (2023)Open reference
-
GDF15: Also known as MIC-1 (Macrophage Inhibitory Cytokine-1), NAG-1 (Non-Steroidal Anti-Inflammatory Drug-Activated Gene), and PTGFB (Placental Transforming Growth Factor Beta)
-
GDF11: Known as BMP-11 (Bone Morphogenetic Protein-11), involved in embryonic patterning and tissue development
Both proteins are synthesized as precursor molecules that undergo proteolytic cleavage to produce the mature, biologically active form. 2GDF15: an emerging therapeutic target for metabolic disorders and cachexia (2023)Open reference
Expression Patterns
GDF15 is expressed in virtually all tissues but is highly expressed in: 3GDF15 in Alzheimer's disease: biomarker and therapeutic implications (2024)Open reference
-
Placenta
-
Liver
-
Kidney
-
Brain (particularly in regions involved in energy homeostasis)
-
Adipose tissue
-
Muscle
GDF11 expression is more restricted, with high levels in: 4GDF15 and Parkinson's disease: clinical correlations (2023)Open reference
-
Developing nervous system
-
Skeletal muscle
-
Heart
-
Pancreas
TGF-β Family Relationships
GDF15 and GDF11 belong to the TGF-β superfamily but represent a distinct branch separate from classical TGF-βs (TGF-β1, TGF-β2, TGF-β3) and BMPs (Bone Morphogenetic Proteins). They share: 5GDF15 in ALS: disease progression marker (2024)Open reference
-
Type I and Type II receptor binding
-
SMAD-dependent signaling pathways
-
Dimeric structure
Key distinguishing features: 6GFRAL receptor complex and neuroprotection (2023)Open reference
-
GDF15 signals primarily through the GFRAL-RET receptor complex
-
GDF11 signals through activin type I and type II receptors
GFRAL/RET Receptor Complex
Receptor Structure
GDF15 exerts its effects primarily through a unique receptor complex: 7GDF11 and neurogenesis in aging (2023)Open reference
-
GFRAL (Glial Cell Line-Derived Neurotrophic Factor Receptor Alpha-Like): The primary binding receptor, expressed predominantly in the brainstem
-
RET (Rearranged During Transfection): The co-receptor that initiates intracellular signaling
This receptor complex was identified as the canonical receptor for GDF15 in 2017, explaining its effects on energy balance and body weight. 8GDF15 in mitochondrial disease (2024)Open reference
Signaling Pathways
Upon GDF15 binding to GFRAL: 9Anti-aging effects of GDF15 modulation (2023)Open reference
-
RET autophosphorylation
-
Activation of PI3K-AKT pathway
-
MAPK/ERK pathway activation
-
PLCγ pathway activation
These downstream pathways regulate: 10GFRAL agonists for neurodegenerative diseases (2024)Open reference
-
Cell survival
-
Metabolic regulation
-
Neuroprotection
Stress-Regulated Expression
Cellular Stress
GDF15 expression is dramatically upregulated by various cellular stresses:
-
Oxidative stress: ROS accumulation induces GDF15 transcription via NRF2
-
Endoplasmic reticulum stress: UPR pathways activate GDF15 expression
-
Mitochondrial dysfunction: Impaired mitochondrial function increases GDF15
-
Inflammatory cytokines: IL-6, TNF-α, and IL-1β stimulate GDF15 expression
Systemic Stress
GDF15 serves as a biomarker of systemic stress:
-
Tissue injury
-
Cancer
-
Cardiovascular disease
-
Metabolic syndrome
Anorexia/Cachexia Connection
Appetite Regulation
GDF15 acts as a potent anorexigenic (appetite-suppressing) cytokine:
-
Activates GFRAL-expressing neurons in the area postrema and nucleus tractus solitarius
-
Induces satiety signals
-
Reduces food intake
-
Promotes weight loss
Cachexia
Elevated GDF15 levels are associated with cancer cachexia and wasting syndromes:
-
Marker of cachexia severity
-
Therapeutic target for cachexia management
-
Correlates with mortality in chronic diseases
Neuroprotective Effects
Neuronal Survival
GDF15 exerts neuroprotective effects through multiple mechanisms:
-
Anti-apoptotic effects: Activates PI3K-AKT pathway to inhibit apoptosis
-
Antioxidant properties: Upregulates NRF2-dependent antioxidant genes
-
Anti-inflammatory effects: Modulates microglial activation
-
Mitochondrial protection: Preserves mitochondrial function
-
Synaptic plasticity: Supports synaptic formation and function
Neurogenesis
GDF11 has been shown to:
-
Promote neurogenesis in the subventricular zone
-
Enhance neuronal differentiation
-
Improve cognitive function in aging
Anti-Aging Potential
Circulating GDF15 and Aging
-
GDF15 levels increase with age in humans and mice
-
Higher baseline GDF15 predicts mortality
-
Associated with age-related diseases
Longevity
-
GDF15 overexpression extends lifespan in model organisms
-
GDF15 deficiency accelerates age-related phenotypes
-
Therapeutic potential for anti-aging interventions
Alzheimer’s Disease Mechanisms
GDF15 in AD
-
Elevated GDF15 levels in AD patients correlate with disease severity
-
Associated with hippocampal atrophy
-
Linked to cognitive decline
Therapeutic Implications
-
GDF15 modulation may affect amyloid and tau pathology
-
GDF15’s metabolic effects may influence AD progression
-
GFRAL agonists under investigation for cognitive enhancement
Parkinson’s Disease Mechanisms
GDF15 in PD
-
Increased GDF15 in PD patients
-
Associated with motor severity
-
Correlates with non-motor symptoms
Neuroprotection Potential
-
Protects dopaminergic neurons from oxidative stress
-
May influence alpha-synuclein pathology
-
GFRAL signaling supports neuronal survival
ALS Mechanisms
GDF15 in ALS
-
Elevated GDF15 in ALS patients
-
Correlates with disease progression
-
Potential biomarker for disease staging
Therapeutic Targeting
-
GDF15 axis modulation as therapeutic strategy
-
GFRAL agonists may support motor neuron survival
Therapeutic Strategies
GFRAL Agonists
-
Small molecule GFRAL agonists in development
-
GDF15 analogs for metabolic applications
-
RET-targeted approaches
GDF15 Neutralization
-
Anti-GDF15 antibodies for cachexia treatment
-
Soluble receptor constructs
-
siRNA approaches
Combination Approaches
-
GDF15 modulation with standard-of-care
-
Targeting multiple pathways
-
Personalized medicine approaches
Mermaid Pathway Diagram
flowchart TD
A["Cellular Stress"] -->|"Oxidative/ER/Mitochondrial"| B["GDF15 Expression"]
B --> C["GFRAL-RET Complex"]
C --> D{"PI3K-AKT Pathway"}
C --> E{"MAPK/ERK Pathway"}
D --> F["Anti-apoptotic Effects"]
D --> G["Mitochondrial Protection"]
E --> H["Cell Survival"]
E --> I["Synaptic Plasticity"]
F --> J["Neuroprotection"]
G --> J
H --> J
I --> J
J --> K["Alzheimer's Disease"]
J --> L["Parkinson's Disease"]
J --> M["A LS"]
N["GDF11"] --> O["Activin Receptors"]
O --> P["SMAD Signaling"]
P --> Q["Neurogenesis"]
Q --> J
B --> R["Anorexia/Cachexia"]
R --> S["Weight Loss"]
R --> T["Energy Homeostasis"]
style J fill:#0e2e10
style K fill:#FFB6C1
style L fill:#FFB6C1
style M fill:#FFB6C1See Also
External Links
Recent Research Updates (2024-2026)
References
- GDF15 and aging: mechanisms and therapeutic potential (2023)
- GDF15: an emerging therapeutic target for metabolic disorders and cachexia (2023)
- GDF15 in Alzheimer's disease: biomarker and therapeutic implications (2024)
- GDF15 and Parkinson's disease: clinical correlations (2023)
- GDF15 in ALS: disease progression marker (2024)
- GFRAL receptor complex and neuroprotection (2023)
- GDF11 and neurogenesis in aging (2023)
- GDF15 in mitochondrial disease (2024)
- Anti-aging effects of GDF15 modulation (2023)
- GFRAL agonists for neurodegenerative diseases (2024)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.